|
Lucinda Osborne is a partner based in our London office. A UK-qualified solicitor with more than 15 years experience, Ms. Osborne is a member of the firm’s corporate and intellectual property practice groups and concentrates on transactional matters for pharmaceutical and biotech clients. She regularly advises clients in connection with their in and out-licensing activities, joint ventures, and collaborations and other strategic transactions, as well as the full range of commercial agreements that span the product life-cycle in the life sciences sector. Her expertise includes clinical trial agreements, evaluation agreements, manufacturing and supply arrangements, distribution and other marketing agreements, and tenders. She has particular experience structuring and documenting global collaborations to reflect market practices and requirements in the United States. In addition to her work in the life sciences industry, Ms. Osborne has broad experience as a corporate lawyer, including advising clients in their acquisitions, dispositions, and financings.
Representative Matters
- Represented Amyris, Inc. which operates an industrial synthetic biology platform, in a partnership with Total, an international oil and gas company, to develop products under a wide-spectrum master development and collaboration agreement.
- Represented Intercell AG in connection with its acquisition of Cytos Biotechnology Ltd’s platform technology for monoclonal antibody discovery.
- Advised Boehringer Ingelheim Vetmedica Inc. in its acquisition of certain animal health products divested by Wyeth and Pfizer Inc. pursuant to an FTC consent order entered into in connection with Pfizer Inc.’s acquisition of Wyeth.
- Represented UCB in connection with its strategic partnership with Wilex AG pursuant to which Wilex acquired world-wide rights to develop UCB's preclinical oncology portfolio, comprising two small-molecule programmes and three antibody programmes, and UCB retained exclusive rights to re-purchase each of those five programmes, following completion of initial clinical feasibility studies for each programme.
- Continues to advise Emergent BioSolutions, on a variety of ongoing strategic transactions in Europe with past representations including the creation of its joint venture and related licensing and commercial arrangements with the University of Oxford and its technology transfer office, Isis Innovation Limited, to further develop MVA85A, thought to be the world’s most clinically advanced vaccine candidate for the prevention of tuberculosis.
Honors and Rankings
- Legal 500 UK, Pharmaceuticals and Biotechnology (2010-2011)
- PLC’s Life Sciences, Which Lawyer?, Commercial & Partnering (2006-2010)
Publications and Speeches
- "Negotiation of Life Sciences Collaboration and Licence Agreements," Negotiating, Understanding and Drafting Commercial Contracts for the Pharmaceutical Industry Seminar (11/14/2011)
- "Early Licensing and R&D," Pharmaceutical Law Summer School, London (7/18/2008)
- "Joint Research and Development Arrangements," Transactions in the Life Sciences Sector (4/24/2007)
|
|